HIGH GRADE SEROUS OVARIAN CANCER
Clinical trials for HIGH GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells target Hard-to-Treat cancers in new trial
Disease control TerminatedThis study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a daily pill keep BRCA-Linked ovarian cancer at bay?
Disease control OngoingThis Phase 3 trial is investigating whether the drug olaparib can help women with a specific type of ovarian cancer stay in remission longer. The study includes women whose cancer has returned but responded well to platinum-based chemotherapy, and who carry a BRCA gene mutation. …
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Immune cells Re-Trained to fight Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial investigates whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), can be re-stimulated in the lab and infused back to fight platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Participants receive their r…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Immune-boosting drug shows promise in ovarian cancer fight
Disease control OngoingThis early-phase study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced ovarian, fallopian tube, or primary peritoneal cancer. About 18 people with stage III or IV cancer will receive the combination. The main goal is to me…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims to outsmart resistant ovarian cancer
Disease control OngoingThis Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug may delay return of ovarian cancer
Disease control OngoingThis study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for ovarian cancer: drug may delay return of disease
Disease control OngoingThis study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC